GSK四价灭活季节性流感疫苗在比利时、德国和西班牙的安全性:2019/2020季节被动增强安全性监测研究
该被动增强安全性监测研究在比利时、德国和西班牙开展,共1082名接种GSK四价灭活季节性流感疫苗者填写免疫后7天内不良反应卡片。首剂后39.2%报告至少1项不良事件,第二剂后7.8%报告不良事件,最常见为全身性疾病及给药部位反应;接种后7天内未报告与疫苗相关的严重不良事件。
要点
- 首剂后39.2%报告至少1项不良事件,最常见为全身性疾病及给药部位反应。
- 第二剂后7.8%报告至少1项不良事件,最常见仍为全身性疾病及给药部位反应。
- 接种后7天内未报告与GSK四价灭活流感疫苗相关的严重不良事件。
核心结论
- 接种GSK四价灭活季节性流感疫苗后7天内未报告相关严重不良事件,支持其良好的风险-获益安全性特征。
研究设计与样本
- 在比利时、德国和西班牙开展的被动增强安全性监测研究,共纳入1082名接种GSK四价灭活季节性流感疫苗的成人和儿童,其中115名小于9岁儿童接种两剂。
主要发现
- 首剂后39.2%报告至少1项不良事件,最常见类别为「全身性疾病及给药部位反应」。
- 首剂后不良事件报告率在18-65岁成人中为47.2%,6月龄-17岁儿童中为38.1%,大于65岁成人中为31.6%。
- 第二剂后7.8%报告至少1项不良事件,最常见类别仍为「全身性疾病及给药部位反应」。
- 接种后7天内未报告与GSK四价灭活流感疫苗相关的严重不良事件。
临床怎么用
- 临床可依据该监测结果向接种者说明首剂后不良事件以全身性疾病及给药部位反应为主,第二剂后报告率较低。
局限性
- 原文未报告该研究的局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Seasonal influenza infects millions annually in Europe. Annual influenza vaccination is the most effective measure to reduce the risk of infection and its complications, especially among young children and older adults. OBJECTIVE: We assessed adverse event (AE) frequency after receiving GSK's inactivated quadrivalent seasonal influenza vaccine (IIV4). METHODS: A passive enhanced safety surveillance study was conducted in Belgium, Germany, and Spain. Adults who had received GSK's IIV4 or the parent(s)/guardian(s)/legally acceptable representative(s) of children given the vaccine were invited to complete an adverse drug reaction (ADR) card to document AEs experienced within 7 days post vaccination. RESULTS: A total of 1082 participants (51.6% females) received GSK's IIV4, including 115 children < 9 years of age who received two doses. The ADR card return rate was 97.0% (n = 1049) after dose 1 and 100% (n = 115) after dose 2. All participants in Belgium and Germany were adults. In Spain, 71.2% were children. After dose 1, 39.2% reported one or more AE. The most frequent AEs category was "general disorders and administration site conditions" (GDASC). AEs were most frequently reported in adults aged 18-65 years (47.2%), followed by children aged 6 months-17 years (38.1%), and adults aged > 65 years (31.6%). After dose 2, 7.8% reported one or more AE, and GDASC was again the most frequent AE category. There were no serious AEs related to GSK's IIV4 within 7 days post vaccination. CONCLUSION: No serious AEs related to GSK's IIV4 within 7 days post vaccination were reported. This study supports the favourable risk-benefit safety profile of GSK's IIV4. Seasonal influenza infects millions annually in Europe, especially young children and older adults. Annual influenza vaccination is the most effective measure to reduce the risk of infection and its complications. As the wild influenza virus strains change every year, the composition of the influenza vaccine changes as well. Since the vaccine is produced in the same way over the years, extensive safety studies are no longer required by regulatory authorities. Instead, monitoring of any unwanted medical incidents (adverse events) after vaccination is required. For the 2019/2020 season, we monitored the adverse events reported by a representative sample of people in Belgium, Germany, and Spain within 7 days after receiving GSK's seasonal influenza vaccine.Of the 1082 people who received the first dose of the vaccine, 39% reported at least one adverse event, such as pain and swelling at the injection site, tiredness, fever, headache, or dizziness. A total of 115 children under 9 years of age received two doses 4 weeks apart. After their second dose, few of these children (8%) reported adverse events. The most frequent adverse events were fever, swelling and pain at the injection site, runny nose, or irritability. No serious adverse events were reported after either the first or second dose.No serious adverse events related to GSK’s seasonal influenza vaccine within the 7 days after vaccination were reported. This study supports the favourable risk–benefit safety profile of GSK's seasonal influenza vaccine.
引用
- Salamanca de la Cueva I, Cinconze E, Eckermann T, et al. Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season. Drug Saf. 2021. PMID: 34694589. doi:10.1007/s40264-021-01121-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。